Wuxi Bio 1H26 revenue is expected to grow steadily; Nomura maintains Buy and slightly raises target price

Overview

This report is Nomura's 1H26 earnings preview and FY26 forecast revision for Wuxi Bio. The report believes the company's operating fundamentals remain solid, with revenue growth driven by early-stage R&D services, late-stage manufacturing, and commercial projects, while short-term profit is dragged down by unfavorable foreign exchange effects and investment losses.

Core views

The core view is that revenue remains resilient, with 1H26 revenue expected to reach CNY11.5bn, up 15.5% year over year; by segment, pre-IND, early-stage services, and late-stage manufacturing revenue are expected to grow 12%, 18%, and 18% year over year, respectively. Profit faces more evident pressure, with gross margin expected to edge down 0.7 percentage points to 42.0%, operating margin down 0.9 percentage points to 27.8%, and net profit attributable to shareholders expected to decline 15% year over year. Nomura remains positive on the medium-term revenue growth outlook and maintains its Buy rating.

Analysis framework

The report uses a framework of earnings forecast revisions, segment revenue breakdown, margin analysis, foreign exchange impact assessment, and DCF valuation to update revenue, earnings, valuation multiples, and cash flow for 1H26 and FY26-FY28.

Methodology notes

• Valuation methodsDCF

  Discounted cash flow valuation

  The target price of HKD51.38 is based on a DCF model, assuming a WACC of 10.1%, a terminal growth rate of 4.0%, and using the Hang Seng Index as the benchmark index.

• Earnings forecastSegment revenue and margin forecast

  Break down revenue by business stage and assess margin changes

  The report separately forecasts growth in pre-IND, early-stage services, late-stage manufacturing, and commercial manufacturing projects, and revises profit forecasts based on changes in FX and investment income.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Wuxi Bio (2269.HK)

  Covered company, a Hong Kong-listed biologics CDMO/open-access biologics technology platform company

  Strengths

  A global open-access biologics technology platform providing one-stop services from discovery and development to commercial manufacturing; as of end-2025, it had 945 integrated projects, including 463 pre-clinical projects, 383 early-stage clinical projects, 74 phase III projects, and 25 commercial manufacturing projects.

  Weaknesses

  Short-term earnings are sensitive to FX and investment income volatility; 1H26 profit is expected to decline year over year.

  Comparison

  The current share price corresponds to about 28.7x FY26F fully diluted EPS, and FY27F and FY28F valuation multiples are expected to decline as earnings grow.

  Risks

  Intensifying global competition, geopolitical tensions, adverse FX movements, and worse-than-expected investment losses.

Key data

• 1H26F revenueCNY11.5bnUp 15.5% year over year.
• 1H26F net profit attributable to shareholdersCNY2.0bnDown about 15% year over year, dragged down by investment losses and FX impact.
• 1H26F gross margin42.0%Down 0.7 percentage points year over year.
• 1H26F operating margin27.8%Down 0.9 percentage points year over year.
• 2H26F revenueCNY13.6bnExpected to grow 15.1% year over year.
• 2H26F net profit attributable to shareholdersCNY2.9bnExpected to grow 14.0% year over year, with the impact of non-recurring items expected to ease.
• FY26F revenue forecastCNY25.123bnLowered by 1.9% versus the previous forecast.
• FY26F reported net profit forecastCNY4.911bnEarnings forecast lowered by 14.0%.
• FY26F fully diluted EPSCNY1.16The current share price implies about 28.7x FY26F fully diluted EPS.
• Target priceHKD51.38Raised from HKD50.54, implying 30.9% upside.
• Current priceHKD39.24As of 2026-07-23.
• Market capitalizationUSD20,664.0mnAs disclosed in the report.

Impact & implications

The report's investment implication is tilted positive: short-term profit forecasts were cut significantly, reflecting pressure from FX and investment losses; however, the revenue growth target remains intact and the medium-term growth outlook has been raised, indicating that Nomura places greater weight on the support from orders and commercial projects for long-term cash flow. The target price was raised slightly and the Buy rating was maintained, suggesting the valuation conclusion remains optimistic.

Risks

• Intensifying global competition may pressure orders, pricing, or margins.
• Geopolitical tensions may affect cross-border customer cooperation and the biopharmaceutical supply chain.
• A weaker USD against RMB may continue to create FX pressure.
• Investment losses or non-recurring items may cause earnings to miss expectations.
• If company earnings diverge from forecasts, target price realization may be hindered.

What to watch

• Whether actual 1H26 revenue comes close to CNY11.5bn and 15.5% year-over-year growth.
• Whether the three segments of pre-IND, early-stage services, and late-stage manufacturing achieve about 12%, 18%, and 18% year-over-year growth, respectively.
• Whether large commercial manufacturing projects each contribute more than USD100mn in revenue in 2026 as management expects.
• Whether gross margin and operating margin continue to be dragged down by FX.
• Whether the impact of non-recurring items eases in 2H26 and net profit returns to year-over-year growth.
• Whether management maintains its 2026 revenue growth target and medium-term revenue growth guidance.